araag2/HINT huggingface dataset:
Clinical trial NCT00381810 (phase 3, status: terminated)
Conditions: lupus erythematosus, systemic
ICD codes: M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, M32.8
Drugs: rituximab, methylprednisolone, acetaminophen, diphenhydramine
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, CC1=CC(O)=CC(C)=C1Cl, CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1
Reason stopped: 
    during a safety review of studies u2970g and u2971g, the data monitoring committee recommended
    that enrollment in this extension trial be terminated.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with systemic lupus erythematosus (SLE) who participated and satisfactorily
             completed their Week 52 evaluation in Study U2971g.

          -  For partial clinical response (PCR) or nonclinical response (NCR), active disease at
             screening as defined by one or more domains with a British Isles Lupus Assessment
             Group (BILAG) A score or 2 or more domains with a BILAG B score.

        Exclusion Criteria:

          -  Subjects who were withdrawn from study U2971g because of protocol non-compliance or
             for safety issues.

          -  Any safety concern potentially attributed to rituximab that in the investigator's
             opinion would jeopardize subject safety.

          -  Subjects who were withdrawn from study U2971g and received rituximab rescue therapy
             outside of the protocol.

          -  Subjects, that in the investigator's opinion, have not demonstrated any clinical
             improvement by Week 52 in study U2971g and in whom the proposed therapy would
             represent risk without benefit.

          -  Unstable subjects with thrombocytopenia experiencing or at high risk for developing
             clinically significant bleeding or organ dysfunction requiring therapies such as
             plasmapheresis or acute blood or platelet transfusions.

          -  Pregnant women or nursing (breastfeeding) mothers.

          -  History of severe, allergic, or anaphylactic reactions to humanized or murine
             monoclonal antibodies.

          -  Known active infection of any kind (excluding fungal infection of nail beds) or any
             major episode of infection requiring hospitalization or treatment with intravenous
             (IV) antibiotics within 8 weeks of screening or oral antibiotics within 2 weeks prior
             to screening.

          -  History of cancer, including solid tumors, hematological malignancies, and carcinoma
             in situ.

          -  Major surgery within 4 weeks prior to screening.

          -  Intolerance or contraindication to oral or IV corticosteroids.

          -  Positive hepatitis B surface antigen (BsAg) or hepatitis C serology.

          -  Receipt of a live vaccine within 28 days prior to treatment.
Clinical trial NCT00131638 (phase 3, status: completed)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: placebo, palifermin
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  History of histologically documented squamous cell carcinoma ( AJCC [American Joint
             Committee on Cancer] Stage II, III, IVA or IVB) involving either the oral cavity,
             oropharynx, hypopharynx, or larynx,post surgical resection (R0, R1) and candidates for
             adjuvant RT/CT

          -  Radiation treatment field to receive planned dose of at least 50Gy to area of the oral
             cavity/oropharynx mucosa that can be visualized

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2

          -  Functional hematopoietic and hepato-renal systems

        Exclusion Criteria:

          -  Tumors of the lips, paranasal sinuses, salivary glands, or unknown primary tumors

          -  Metastatic disease (M1) Stage IV C

          -  Presence or history of any other primary malignancy (other than curatively treated in
             situ cervical cancer or basal cell carcinoma of the skin)

          -  History of chronic pancreatitis or episode of acute pancreatitis within the last year

          -  Prior radiation to the site of the disease, or prior chemotherapy-
Clinical trial NCT00082927 (phase 3, status: completed)
Conditions: metastatic cancer, pain, prostate cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52, C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: ibandronate sodium
SMILES: CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed primary prostate cancer OR sclerotic bone
             metastases (for patients with serum prostate-specific antigen > 100 ng/mL)

          -  Radiologically confirmed bone metastases by plain x-ray, isotope scan, CT scan, or MRI

          -  Clinical diagnosis of metastatic bone pain for which radiotherapy is indicated

          -  Single localized metastatic bone pain AND receiving optimal analgesics and adjuvant
             drugs, including non-steroidal anti-inflammatory drugs, unless contraindicated

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age

          -  Over 18

        Sex

          -  Male

        Menopausal status

          -  Not specified

        Performance status

          -  Not specified

        Life expectancy

          -  At least 3 months

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Creatinine ≤ 3.0 mg/dL

          -  No hypercalcemia (corrected calcium > 10.8 mg/dL)

          -  No hypocalcemia (corrected calcium < 8.2 mg/dL)

        Other

          -  No known hypersensitivity to ibandronate or other bisphosphonates

          -  No history of aspirin-sensitive asthma

          -  Able to comply with pain chart and quality of life assessments

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  More than 4 weeks since prior change in systemic chemotherapy

          -  No prior high-dose chemotherapy (dose intensity > 3 times standard dose)

        Endocrine therapy

          -  More than 4 weeks since prior change in hormonal therapy

        Radiotherapy

          -  See Disease Characteristics

          -  No prior external beam radiotherapy to index site

          -  No prior systemic radioisotope therapy (e.g., strontium chloride Sr 89 or samarium Sm
             153 lexidronam pentasodium)

        Surgery

          -  Not specified

        Other

          -  More than 6 months since prior bisphosphonate treatment

          -  More than 4 weeks since prior aminoglycoside antibiotics

          -  More than 30 days since prior investigational drugs
Clinical trial NCT00044681 (phase 3, status: completed)
Conditions: depressive disorder, depressive disorder, major, depression
ICD codes: F25.1, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40, F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: risperidone
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Meet criteria of Diagnostic and Statistical Manual of Mental Diseases, 4th edition
             (DSM-IV), for Major Depressive Disorder

          -  history of resistance to therapy with antidepressant medication

          -  score on the Hamilton Rating Scale of Depression (HAM-D) of >=20 at start of study.

        Exclusion Criteria:

          -  Meet DSM-IV criteria for Axis I disorder (except anxiety disorders) or borderline
             personality disorder

          -  substance dependence, including drugs of abuse and alcohol

          -  history of schizophrenia, bipolar disorder, or manic episode

          -  meet DSM-IV criteria for delirium, dementia, amnesic or other cognitive disorder
             supported by Mini Mental Status Examination (MMSE)

          -  pregnant or nursing females, or those lacking adequate contraception.
Clinical trial NCT00503399 (phase 3, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: teriparatide, risedronate
SMILES: OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Ambulatory men 25 years of age and older presenting to Visit 1 with a bone mineral
             density (BMD) of at least 1.5 standard deviation (SD) below the corresponding normal
             young adult men average BMD (T score of -1.5 or lower), as determined from the
             manufacturer's database at any of the following regions of interest: total hip,
             femoral neck, or lumbar spine

          -  Have received glucocorticoid therapy at an average dose of at least 5.0 milligrams
             (mg) per day of prednisone or its equivalent for a minimum of 3 consecutive months
             immediately preceding screening (Visit 1), as determined by medical history.

          -  A minimum of 2 lumbar vertebrae (L) in the L-1 through L-3 region must be evaluable by
             quantitative computerized tomography.

          -  Normal or clinically insignificant abnormal laboratory values (as determined by the
             investigator) including serum calcium, parathyroid hormone (PTH) (1 84), and 25
             hydroxyvitamin D concentrations, and alkaline phosphatase activity.

        Exclusion Criteria:

          -  Presence of a mild, moderate, or severe spinal fracture in both the twelfth thoracic
             vertebra (T-12) and first lumbar vertebra (L-1), as determined by the central reading
             facility using the semiquantitative technique.

          -  Abnormal albumin-corrected serum calcium levels

          -  History of unresolved skeletal diseases that affect bone metabolism other than
             glucocorticoid-induced osteoporosis

          -  History of malignant neoplasms in the 5 years prior to Visit 2, with the exception of
             superficial basal cell or squamous cell carcinomas of the skin that have been
             definitively treated. Increased baseline risk of osteosarcoma; this includes patients
             with Paget's disease of the bone, previous primary skeletal malignancy, or skeletal
             exposure to therapeutic irradiation.

          -  Abnormal thyroid function not corrected by therapy

          -  Past and/or current treatment with certain medications.
Clinical trial NCT00545103 (phase 3, status: completed)
Conditions: diverticulitis
ICD codes: K57.00, K57.01, K57.12, K57.13, K57.20, K57.21, K57.32
Drugs: spd476, mmx™ mesalazine, 1.2g extended release tablet, spd476, mmx™ mesalazine, 1.2g extended release tablet, spd476, mmx™ mesalazine, 1.2g extended release tablet, placebo
SMILES: NC1=CC(C(O)=O)=C(O)C=C1, NC1=CC(C(O)=O)=C(O)C=C1, NC1=CC(C(O)=O)=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Males and females =>18yrs of age.

          2. If female of childbearing potential (FOCP), has demonstrated a negative beta HCG
             (human chorionic gonadotropin) serum pregnancy test, and agrees to comply with any
             applicable contraceptive requirements of the protocol

          3. An episode of acute diverticulitis that resolved without colonic resection.

          4. Confirmation of diverticulosis via endoscopic evaluation of the sigmoid colon with at
             least three diverticula noted

        Exclusion Criteria:

          1. Previous colorectal surgery, including surgical intervention for diverticular disease
             (with the exception of haemorrhoidectomy, colonic removal of polyps, and appendectomy)

          2. Active peptic ulcer disease

          3. History of or current presence of inflammatory bowel disease (IBD)

          4. Subjects with active irritable bowel syndrome (IBS) requiring ongoing medication

          5. Allergy or hypersensitivity to aspirin or related compounds

          6. Allergy to radiologic contrast agents

          7. Use of another Investigational product within 30 days of Baseline

          8. Use of antibiotic therapy within 4 weeks of Baseline

          9. Within 14 days of Baseline, use of prebiotic, probiotic or 5-ASA medications, as well
             as drugs active at the 5HT-receptor or anti-spasmodic agents

         10. Use of systemic or rectal steroids within 6 weeks of Baseline. Use of inhaled or nasal
             steroids is acceptable

         11. Use of anti-inflammatory drugs, (NSIADs, COX-2 inhibitors) including aspirin (except
             for cardiac prophylaxis) and ibuprofen, on a regular and ongoing basis

         12. History of alcohol or other substance abuse within the previous year

         13. Active or recent history of endometriosis or dysmenorrhoea within 6 months prior to
             Baseline

         14. Females who are lactating
Clinical trial NCT00483652 (phase 3, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: fampridine-sr, placebo
SMILES: NC1=CC=NC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient with clinically defined multiple sclerosis

          -  All patients must be able to complete two trials of a timed 25 foot walk

        Exclusion Criteria:

          -  Female patients who are either pregnant or breastfeeding.
Clinical trial NCT00171002 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: valsartan/amlodipine
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with uncomplicated, essential hypertension

        Exclusion Criteria:

          -  Severe hypertension

          -  History of stroke, myocardial infarction, heart failure, chest pain, abnormal heart
             rhythm

          -  Liver, kidney, or pancreas disease

          -  Insulin dependent diabetes

          -  Allergy to certain medications used to treat high blood pressure

        Other protocol-defined exclusion criteria may apply.
Clinical trial NCT01510535 (phase 3, status: completed)
Conditions: osteoarthritis of the knee
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: placebo, hyruan plus, lbsa0103
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Over 40 years of age

          -  Kellgren & Lawrence grade I-III

          -  If there is more than one knee having a weight bearing pain of at least 40mm evaluated
             by 100mm VAS

          -  Be willing to discontinue all nonsteroidal anti-inflammatory drugs(NSAIDs),
             analgesics, condroichin sulfate/glucosamine or physical therapy for the duration of
             the study

        Exclusion Criteria:

          -  Body mass index > 32

          -  Have rheumarthritis

          -  Patients who have a weight-bearing pain of less than 40mm on both knees when measured
             by 100mm-VAS

          -  Have Sudek's atrophy, Paget's disease, Spinal disc herniation

          -  Kellgren & Lawrence Grade IV
Clinical trial NCT01314716 (phase 3, status: completed)
Conditions: bronchiectasis
ICD codes: J47.9, Q33.4, J47.1, J47.0
Drugs: azli, placebo
SMILES: C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(=O)O)\C2=CSC([NH3+])=N2)C(=O)N1S([O-])(=O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male/Female 18 years or older with non-CF bronchiectasis

          -  Chronic sputum production on most days

          -  Positive sputum culture for gram-negative organisms

          -  Must have met lung function requirements

        Exclusion Criteria:

          -  History of CF

          -  Hospitalized within 14 days prior to joining the study

          -  Previous exposure to AZLI

          -  Pregnant, breastfeeding, or unwilling to follow contraceptive measures for the study

          -  Must have met liver and kidney function requirements

          -  Continuous oxygen use of greater than 2 liters per minute (supplemental oxygen with
             activity and at night was allowed)

          -  Treatment for nontuberculous mycobacteria infection or active mycobacterium
             tuberculosis infection within 1 year of enrollment

          -  Other serious medical conditions.
Clinical trial NCT01177384 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin phosphate, comparator: placebo, acarbose, glimepiride
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN(C)C(=N)NC(N)=N, CC1=CC(O)=CC(C)=C1Cl, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  has T2DM and is on acarbose alone at a stable dose of at least 50 mg t.i.d.(three
             times a day) for at least 10 weeks or on acarbose at a stable dose of at least 50 mg
             t.i.d. (three times a day) for at least 10 weeks in combination with another
             antihyperglycemic agent (AHA)

          -  is at least 18 years of age (for participants in India: between 18 and 65 years of
             age)

          -  male or female who is unlikely to conceive (not of reproductive potential, or agrees
             to remain abstinent or use [or have partner use] acceptable birth control if of
             reproductive potential)

        Exclusion Criteria:

          -  has a history of type 1 diabetes mellitus

          -  use of thiazolidinedione (TZD), dipeptidyl peptidase-4 (DPP-4) inhibitors,
             glucagon-like peptide-1 (GLP-1) receptor agonists, or insulin

          -  has the following cardiovascular disorders: acute coronary syndrome; new or worsening
             symptoms of coronary heart disease; coronary artery intervention; stroke or transient
             ischemic neurological disorder

          -  has liver or kidney disease

          -  has cancer or any clinically significant disease or disorder as judged by the
             Investigator
Clinical trial NCT00630487 (phase 3, status: terminated)
Conditions: growth hormone deficiency
ICD codes: D81.810, E53.0, E53.1, E61.0, E61.1, E61.2, E61.3
Drugs: placebo, somatropin
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    see termination reason in detailed description.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females between 18 and 65 years of age

          -  Isolated growth hormone deficiency

        Exclusion Criteria:

          -  Isolated growth hormone deficiency by childhood onset

          -  Diabetes mellitus type 1 or 2
Clinical trial NCT00253214 (phase 3, status: completed)
Conditions: alzheimer disease, dementia
ICD codes: G30.8, G30.9, G30.0, G30.1, G31.09, G31.83, F01.50, F01.51, F03.90, F03.91, F18.17
Drugs: galantamine hydrobromide
SMILES: [H][C@]12C[C@@H](O)C=C[C@]11CCN(C)CC3=C1C(O2)=C(OC)C=C3
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatients with a diagnosis of mild-to-moderate Alzheimer's disease according to the
             National Institute of Neurological and Communicative Disorders and the Alzheimer's
             Disease and Related Disorders Association (NINCDS-ADRDA) criteria (including patients
             living in residential homes for the elderly or day patients)

          -  have a Mini-Mental Status Examination (MMSE) score of 10 - 24, and a score of at least
             18 on the cognitive portion of the Alzheimer's Disease Assessment scale (ADAS-cog-11)
             with an onset between ages 40 and 90

          -  history of at least a 6 months of gradual and progressive cognitive decline

          -  have a consistent informant to accompany the patient on scheduled visits

        Exclusion Criteria:

          -  Neurogenerative disorders such as Parkinson's disease

          -  cognitive impairment resulting from acute cerebral trauma, cerebral damage due to a
             lack of oxygen, vitamin deficiency, infections such as meningitis or AIDS, significant
             endocrine or metabolic disease, mental retardation or a brain tumor

          -  dementia caused by small strokes or cerebrovascular disease

          -  having epilepsy, significant psychiatric disease, active peptic ulcer, clinically
             significant liver, kidney or lung disorders, or heart disease

          -  females of child bearing potential without adequate contraception
Clinical trial NCT01181141 (phase 3, status: completed)
Conditions: venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: du-176b (edoxaban), enoxaparin sodium 20mg
SMILES: CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects who are scheduled to undergo surgery within 10 days for fracture of inner or
             outer femoral neck (trochanteric and subtrochanteric)

        Exclusion Criteria:

          -  Subjects with risks of hemorrhage

          -  Subjects with thrombolic risks

          -  Subjects who weigh less than 40 kg

          -  Subjects who are pregnant or suspect pregnancy, or subjects who want to become
             pregnant
Clinical trial NCT01126190 (phase 3, status: completed)
Conditions: chemotherapy-induced neutropenia
ICD codes: D61.810
Drugs: chemotherapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Breast cancer patients scheduled to receive the AT regimen (doxorubicin/ docetaxel)

        Exclusion Criteria:

          -  Subjects may have received no more than 1 prior chemotherapy regimen (including
             adjuvant therapy if given within the last 12 months)
Clinical trial NCT00278941 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: quetiapine fumarate sustained release
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Documented clinical diagnosis according to the DSM-IV (Diagnostic and Statistical
             Manual of Mental Disorders, 4th edition, text revision) meeting criteria 296.2x Major
             Depressive Disorder,

          -  Single Episode, or 296.3x Major Depressive Disorder,

        Exclusion Criteria:

          -  Patients with a DSM-IV Axis I disorder other than MDD w/in 6 months of enrollment,

          -  Patients with a diagnosis of DSM-IV Axis II disorder which has a major impact on the
             patients current psychiatric status.

          -  Patients whose current episode of depression>12 months or <4 weeks from enrollment